Repeatability of SUV measurements in serial PET.
暂无分享,去创建一个
H Kalaigian | S M Larson | J L Humm | S. Nehmeh | J. Humm | S. Larson | M. Gonen | H. Schoder | H. Kalaigian | H. Schöder | S A Nehmeh | H Schoder | J. Schwartz | J Schwartz | M Gonen | M. Gonen | Steven M. Larson | Jazmin Schwartz
[1] G van Kaick,et al. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[2] Douglas G. Altman,et al. Measurement in Medicine: The Analysis of Method Comparison Studies , 1983 .
[3] I. Buvat,et al. Partial-Volume Effect in PET Tumor Imaging* , 2007, Journal of Nuclear Medicine.
[4] M. Schwaiger,et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] R. Boellaard,et al. Repeatability of 18F-FDG PET in a Multicenter Phase I Study of Patients with Advanced Gastrointestinal Malignancies , 2009, Journal of Nuclear Medicine.
[6] Paul E Kinahan,et al. Dual Energy CT Attenuation Correction Methods for Quantitative Assessment of Response to Cancer Therapy with PET/CT Imaging , 2006, Technology in cancer research & treatment.
[7] A. Beckett,et al. AKUFO AND IBARAPA. , 1965, Lancet.
[8] Cesare Guida,et al. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[9] M Schwaiger,et al. Reproducibility of metabolic measurements in malignant tumors using FDG PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[10] K. Herholz,et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.
[11] W. Weber. Chaperoning drug development with PET. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[12] D. Visvikis,et al. Influence of OSEM and segmented attenuation correction in the calculation of standardised uptake values for [18F]FDG PET , 2001, European Journal of Nuclear Medicine.
[13] Wolfgang A Weber,et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Claude Nahmias,et al. Reproducibility of Standardized Uptake Value Measurements Determined by 18F-FDG PET in Malignant Tumors , 2008, Journal of Nuclear Medicine.
[15] J. Leonard,et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[16] R. Hustinx,et al. Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[17] J. Bergh,et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] R. Lufkin,et al. Change induced by radiation therapy in FDG uptake in normal and malignant structures of the head and neck: quantitation with PET. , 1993, Radiology.
[19] Geoffrey McLennan,et al. PET/CT Assessment of Response to Therapy: Tumor Change Measurement, Truth Data, and Error. , 2009, Translational oncology.
[20] M Schwaiger,et al. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Paul E Kinahan,et al. Variability in PET quantitation within a multicenter consortium. , 2010, Medical physics.
[22] E Yorke,et al. Four-dimensional (4D) PET/CT imaging of the thorax. , 2004, Medical physics.
[23] L. Clarke,et al. Quantitative imaging for evaluation of response to cancer therapy. , 2009, Translational oncology.
[24] O. Hoekstra,et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[25] Paul Kinahan,et al. Instrumentation factors affecting variance and bias of quantifying tracer uptake with PET/CT. , 2010, Medical physics.
[26] D. Altman,et al. STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.
[27] V. Lowe,et al. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. , 1994, Radiology.
[28] Bruce D Cheson,et al. Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development , 2005, Clinical Cancer Research.
[29] R L Wahl,et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] David W Townsend,et al. Time Course of Early Response to Chemotherapy in Non–Small Cell Lung Cancer Patients with 18F-FDG PET/CT , 2007, Journal of Nuclear Medicine.
[31] H. Minn,et al. [18F]Fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer , 2004, European Journal of Nuclear Medicine.
[32] J M Hoffman,et al. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[33] Y. Yonekura,et al. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[34] Adriaan A. Lammertsma,et al. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[35] Michael Bader,et al. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.